Lung DNA Test

Lung DNA Test For Detecting Transplant Rejections

Capturing small fragments of DNA found circulating in the blood has made the headings – the foundation of liquid biopsy examinations for cancer; however, California-based firm – Natera intends to apply this technology to track the progression of organ transplants.

The firm has now started its genetic Prospera test for lung transplant recipients, adding to its lately established patient monitoring portfolio, which also includes kidney and heart-focused portfolios. Donor-derived, cell-free DNA in transplanted tissues is screened in blood tests, and it analyses the genetic material for indications of rejection.

As per Natera, this can offer a non-invasive monitoring alternative to bronchoscopic biopsy tests by identifying organ injuries and hard-to-spot infections.

The commercialization of the Prospera test comes just a few weeks after clinical data for the diagnostic was announced as a late-breaking presentation at the American College of Chest Physicians’ annual meeting.

Prospective validation analysis by the Ohio State University’s lung transplant program examined 204 blood tests with lung tissue biopsy samples from 104 organ recipients. There were 35 cases of acute organ rejection, and the Prospera test had a negative predictive value of 97.33% to support ruling out the condition.

David Ross

, Natera’s medical director for lung transplantation, stated that the Prospera test had been clinically certified as a mechanism for evaluating kidney and heart rejection in transplant patients, and it’s thrilling to approve it for lung transplant evaluation as well.

Prospera debuted with its heart transplant DNA evaluation test in August, a kidney transplant offering in Sept, and the lung test launch indicates the third in line.

To monitor chronic lung allograft dysfunction, the foremost cause of death amongst organ recipients, Natera intends to compare the Prospera lung diagnostic to the gold standard of transbronchial biopsy methods in the future using a randomized, controlled non-inferiority trial and an observational registry analysis.


Also Read:

Download Biotecnika App for more Updates on Life Sciences, Job vacancies, CSIR-NET, GATE, and a lot more.